Patents by Inventor CHRISTOPHE DEBONNEVILLE

CHRISTOPHE DEBONNEVILLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED ANTIBODIES THAT BIND TO CD19 AND THEIR USES
    Publication number: 20140286934
    Abstract: The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 29; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 31 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 32.
    Type: Application
    Filed: January 30, 2014
    Publication date: September 25, 2014
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Stanislas BLEIN, Darko Skegro, Christophe Debonneville, Martin Bertschinger
  • Humanized antibodies that bind to CD19 and their uses
    Patent number: 8679492
    Abstract: The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 29; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 31 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 32.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: March 25, 2014
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Stanislas Blein, Darko Skegro, Christophe Debonneville, Martin Bertschinger
  • Humanized antibodies that bind to CD19 and their uses
    Publication number: 20100215651
    Abstract: The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 29; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 31 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 32.
    Type: Application
    Filed: February 23, 2010
    Publication date: August 26, 2010
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: STANISLAS BLEIN, DARKO SKEGRO, CHRISTOPHE DEBONNEVILLE, MARTIN BERTSCHINGER